SOX8 and benign prostatic hyperplasia: When combined with previously described targets in a four DMG panel (RASSF1A1, miR129-2, NRIP3, and SOX8) [31] and applied to cfDNA from the blood of a German cohort (PCa n = 39; BPH n = 40; HD n = 90), a risk score integrating methylation data, the cfDNA concentration, patient age, and PSA level improved the specificity for detecting hyperplasia and reduced the over-diagnosis of indolent PCa.